The role of the BDNF (rs6265) and CNTF (rs1800169) gene polymorphic variants in the development and progression of neurological disorders
https://doi.org/10.25789/YMJ.2023.83.25
Abstract
In recent decades the contribution of polymorphic variants of genes encoding neuroinflammation and neuroprotection proteins in pathology of the nervous system has been actively studied. Numerous studies have demonstrated the most important structural and functional role of single nucleotide variants in the BDNF and CNTF genes in the brain. This review provides evidence of the association of polymorphic loci of the BDNF and CNTF genes with a number of neurological disorders. It was found that an increased risk of developing depressive disorders, Alzheimer's and Parkinson's diseases are characteristic of the BDNF rs6265 polymorphism carriers. Moreover, the above mutation affects the length of stay in rehabilitation and the duration of remission in patients with substance dependence. A number of authors provide contradictory information about the relationship of the BDNF rs6265 genetic variant with changes in neurotrophin levels in schizophrenia. The BDNF rs6265 A/A genotype carriers in Caucasian and Asian populations showed an increased risk of the disease. The CNTF rs1800169 genetic variant does not affect the risk of schizophrenia in general but may play a more prominent role in its clinical manifestations together with other CNTF gene mutations. Some studies have shown an association of the rs1800169 polymorphism in the CNTF gene with schizophrenia spectrum disorders. A number of studies have confirmed a negative association between the rs1800169 polymorphism in the CNTF gene and Alzheimer's disease. Further studies are needed to clarify the role of the BDNF and CNTF genetic variants in pathology of the nervous system and to find an effective treatment.
About the Authors
G. M. Bodienkova
ФГБНУ «Восточно-Сибирский институт медико-экологических исследований» (ФГБНУ ВСИМЭИ)
Russian Federation
Russian Federation
BODIENKOVA Galina Mikhailovna – МD, Professor, head of the Lab., corresponding author
M. O. Shchepina
ФГБНУ «Восточно-Сибирский институт медико-экологических исследований» (ФГБНУ ВСИМЭИ)
Russian Federation
Russian Federation
SHCHEPINA Maria Olegovna – junior researcher
References
1. The effect of brain neurotrophic factor gene polymorphism on the effectiveness of therapeutic and rehabilitation measures in patients with psychostimulant dependence / K.N. Poplevchenkov, T.V. Agibalova, M.S. Zastrozhin, O.Zh. Buzik // Neurology Bulletin. 2021. Vol. 53. No. 3. P. 26–32. DOI: 10.17816/nb82801.
2. Lemeshchenko A.V., Tsygan V.N., Kazakova E.A. Polymorphisms of the BDNF (rs6265) and LIPC (rs2043085) genes associated with the violation of military professional activity in the Arctic zone // Voenno-medicinskii zhurnal. 2023. Vol. 344. No. 5. P. 53–63. DOI: 10.52424/00269050_2023_344_5_53.
3. Molecular markers of early development of extraaural effects in pilots / L.P. Kuz'mina, R.A. Nenasheva, L.M. Bezrukavnikova, N.A. Anvarul // Actual problems of occupational medicine: the Collected Works of the Institute / Edit. I.V. Bukhtiyarov. Saratov: Amirit, 2018. P. 154–160.
4. Polymorphic variants of the brain-derived neurotrophic factor gene (rs6265) and their association with the severity of cognitive dysfunction in military personnel / A.V. Lemeshchenko, N.N. Burlov, O.E. Gurskaya [et al.] // Vestnik SurGU. Medicina. 2022. Vol. 4. No. 54. P. 54–60. DOI: 10.34822/2304-9448-2022-4-54-60.
5. Development of a method for the identification of rs6265 polymorphism in the human brain neurotrophic factor gene / G.G. Kutelev, A.B. Krivoruchko, A.E. Trandina [et al.] // Bulletin of the Russian Military Medical Academy. 2021. Vol. 23. No. 4. P. 63–70. DOI: 10.17816/brmma80926.
6. Socio-demographic and case history characteristics of patients with alcohol addiction and gene polymorphism in GABA-glutamate and dopamine systems / A.O. Kibitov, K.V. Rybakova, M.G. Solovyova [et al.] // Social and clinical psychiatry. 2021. Vol. 31. No. 1. P. 5–19.
7. Strambovskaya N.N. Genetic polymorphism of the growth factors in patients with chronic brain ischemia // Far Eastern Medical Journal. 2014. No. 2. P. 49–52.
8. Pharmacogenetic markers of efficacy of alcohol dependence treatment with pregabalin – a modulator of the GABA and glutamate brain systems / A.O. Kibitov, V.M. Brodyansky, K.V. Rybakova [et al.] // Issues of narсology. 2018. Vol. 170. No. 10–11. P. 101–150.
9. Characterization of genetic polymorphisms associated with neurophysiological processes and analysis of their allele frequency distribution in the Russian population / G.G. Kutelev, S.S. Malyshkin, A.B. Krivoruchko [et al.] // Journal of Neurology and Psychiatry by S.S. Korsakov. 2022. Vol. 122. No. 6. P. 122–127. DOI: 10.17116/jnevro2022122061122.
10. A null mutation in the human CNTF gene is not causally related to neurological diseases / R. Takahashi, H. Yokoji, H. Misawa [et al.] // Nat. Genet. 1994. Vol. 7. No. 1. P. 79–84. DOI: 10.1038/ng0594-79.
11. A null mutation within the ciliary neurotrophic factor (CNTF)-gene: implications for susceptibility and disease severity in patients with multiple sclerosis // V. Hoffmann, D. Pöhlau, H. Przuntek, J.T. Epplen, C. Hardt // Genes Immun. 2002. Vol. 3. No. 1. P. 53–55. DOI: 10.1038/sj.gene.6363818.
12. Association between a null mutation in the human ciliary neurotrophic factor (CNTF) gene and increased incidence of psychiatric diseases? / J. Thome, J. Kornhuber, A. Baumer [et al.] // Neurosci. Lett. 1996. Vol. 203. No. 2. P. 109–110. DOI: 10.1016/0304-3940(95)12274-5.
13. Association between BDNF gene variant rs6265 and the severity of depression in antidepressant treatment-free depressed patients / I.S. Losenkov, N.J.V. Mulder, L.A. Levchuk [et al.] // Front. Psychiatry. 2020. No. 11. Article ID 38. DOI: 10.3389/fpsyt.2020.00038.
14. Association of a null mutation in the CNTF gene with early onset of multiple sclerosis / R. Giess, M. Mäurer, R. Linker [et al.] // Arch. Neurol. 2002. Vol. 59. No. 3. P. 407–409. DOI: 10.1001/archneur.59.3.407.
15. Association of BDNF and BCHE with Alzheimer's disease: meta-analysis based on 56 genetic case-control studies of 12,563 cases and 12,622 controls / H. Ji, D. Dai, Y. Wang [et al.] // Exp. Ther. Med. 2015. Vol. 9. No. 5. P. 1831– 1840. DOI: 10.3892/etm.2015.2327.
16. Association of BDNF Val66Met polymorphism and brain BDNF levels with major depression and suicide / M.M. Youssef, M.D. Underwood, Y.-Y. Huang [et al.] // Int. J. Neuropsychopharmacol. 2018. Vol. 21. No. 6. P. 528–538. DOI: 10.1093/ijnp/pyy008.
17. Association of circulating BDNF levels with BDNF rs6265 polymorphism in schizophrenia / P.K. Kumar, P. Mitra, R. Ghosh [et al.] // Behav. Brain Res. 2020. No. 394. Article ID 112832. DOI: 10.1016/j.bbr.2020.112832.
18. Association of rs6265 and rs2030324 polymorphisms in brain-derived neurotrophic factor gene with Alzheimer’s disease: a meta-analysis / Y. Lin, S. Cheng, Z. Xie, D. Zhang // PLoS One. 2014. Vol. 9. No. 4. Article ID e94961. DOI: 10.1371/journal.pone.0094961.
19. BDNF rs6265 variant alters outcomes with levodopa in early-stage Parkinson’s disease / D.L. Fischer, P. Auinger, J.L. Goudreau [et al.] // Neurotherapeutics. 2020. Vol. 17. No. 4. P. 1785– 1795. DOI: 10.1007/s13311-020-00965-9.
20. BDNF Val66Met influences time to onset of levodopa induced dyskinesia in Parkinson’s disease / T. Foltynie, B. Cheeran, C.H. Williams-Gray [et al.] // J. Neurol. Neurosurg. Psychiatry. 2009. Vol. 80. No. 2. P. 141–144. DOI: 10.1136/jnnp.2008.154294.
21. BDNF Val66Met polymorphism and memory decline across the spectrum of Alzheimer's disease / Y.Y. Lim, S.M. Laws, S. Perin [et al.] // Genes Brain Behav. 2021. Vol. 20, No. 5. Article ID e12724. DOI: 10.1111/gbb.12724.
22. Brain-derived neurotrophic factor rs6265 (Val66Met) single nucleotide polymorphism as a master modifier of human pathophysiology / V.T. Nguyen, B. Hill, N. Sims [et al.] // Neural. Regen. Res. 2023. Vol. 18. No. 1. P. 102–106. DOI: 10.4103/1673-5374.343894.
23. Childhood trauma and emotion regulation: the moderator role of BDNF Val66Met / M.I. Bîlc, R. Vulturar, A. Chiș [et al.] // Neurosci. Lett. 2018. Vol. 685. P. 7–11. DOI: 10.1016/j.neulet.2018.07.018.
24. Ciliary neurotrophic factor null allele frequencies in schizophrenia, affective disorders, and Alzheimer's disease / J. Gelernter, C. Van Dyck, D.P. Van Kammen [et al.] // Am. J. Med. Genet. 1997. Vol. 74. No. 5. P. 497–500.
25. Colucci-D’Amato L., Speranza L., Volpicelli F. Neurotrophic Factor BDNF, physiological functions and therapeutic potential in depression, neurodegeneration and brain cancer // Int. J. Mol. Sci. 2020. No. 21. Article ID 7777. DOI: 10.3390/ijms21207777.
26. Does the brain-derived neurotrophic factor Val66Met polymorphism modulate the effects of physical activity and exercise on cognition? / B. De Las Heras, L. Rodrigues, J. Cristini [et al.] // Neuroscientist. 2022. Vol. 28. No. 1. P. 69–86. DOI: 10.1177/1073858420975712.
27. Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial / C. Lavedan, S. Volpi, M.H. Polymeropoulos, C.D. Wolfgang // Pharmacogenomics. 2008. Vol. 9. No. 3. P. 289– 301. DOI: 10.2217/14622416.9.3.289.
28. Effect of BDNF Val66Met on disease markers in dominantly inherited Alzheimer's disease / Y.Y. Lim, J. Hassenstab, A. Goate [et al.] // Ann. Neurol. 2018. Vol. 84. No. 3. P. 424–435. DOI: 10.1002/ana.25299.
29. Genetic markers as risk factors for the development of impulsive-compulsive behaviors in patients with Parkinson’s disease receiving dopaminergic therapy / A. Fedosova, N. Titova, Z. Kokaeva [et al.] // J. Pers. Med. 2021. Vol. 11. No. 12. Article ID 1321. DOI: 10.3390/jpm11121321.
30. Genetic risk factors and markers for Alzheimer's disease and/or depression in the VITA study / E. Grünblatt, S. Zehetmayer, J. Bartl [et al.] // J. Psychiatr. Res. 2009. Vol. 43. No. 3. P. 298–308. DOI: 10.1016/j.jpsychires.2008.05.008.
31. Global, regional, and national burden and attributable risk factors of neurological disorders: The Global Burden of Disease study 1990–2019 / C. Ding, Y. Wu, X. Chen [et al.] // Front. Public Health. 2022. No. 10. Article ID 952161. DOI: 10.3389/fpubh.2022.952161.
32. Investigation of CNTF, COMT, DDR1, DISC1, DRD2, DRD3, and DTNBP1 candidate genes in schizophrenia: results from the Hungarian SCHIZOBANK Consortium / J. Benkovits, S. Magyarosi, A.J. Pulay [et al.] // Neuropsychopharmacol. Hung. 2016. Vol. 18. No. 4. P. 181–187. (In Hungarian).
33. Kheirollahi M., Kazemi E., Ashouri S. Brain-derived neurotrophic factor gene Val66Met polymorphism and risk of schizophrenia: a meta-analysis of case-control studies // Cell. Mol. Neurobiol. 2016. Vol. 36. No. 1. P. 1–10. DOI: 10.1007/s10571-015-0229-z.
34. Lin P.-Y., Tsai G. Meta-analyses of the association between genetic polymorphisms of neurotrophic factors and schizophrenia // Schizophr. Res. 2004. Vol. 71. No. 2–3. P. 353–360. DOI: 10.1016/j.schres.2004.03.018.
35. No association between brain-derived neurotrophic factor G196A polymorphism and clinical features of Parkinson’s disease / M. Svetel, T. Pekmezovic, V. Markovic [et al.] // Eur. Neurol. 2013. Vol. 70. No. 5–6. P. 257–262. DOI: 10.1159/000352033.
36. No association between the CNTF null mutation and schizophrenia or personality / J. Nishiyama, M. Tochigi, S. Itoh [et al.] // Psychiatr. Genet. 2006. Vol. 16. No. 5. P. 217–219. DOI: 10.1097/01.ypg.0000242189.05656.9d.
37. Notaras M., Van den Buuse M. Brain-derived neurotrophic factor (BDNF): novel insights into regulation and genetic variation // Neuroscientist. 2019. Vol. 25. No. 5. P. 434–454. DOI: 10.1177/1073858418810142.
38. Pierce R.C., Bari A.A. The role of neurotrophic factors in psychostimulant-induced behavioral and neuronal plasticity // Rev. Neurosci. 2001. Vol. 12. No. 2. P. 95–110. DOI: 10.1515/revneuro.2001.12.2.95.
39. Schizophrenic psychoses and the CNTF null mutation / Y. Tanaka, H. Ujike, Y. Fujiwara [et al.] // Neuroreport., 1998. Vol. 9. No. 6. P. 981– 983. DOI: 10.1097/00001756-199804200-00005.
40. Suicide attempt, clinical correlates, and BDNF Val66Met polymorphism in chronic patients with schizophrenia / H. Xia, G. Zhang, X. Du [et al.] // Neuropsychology. 2018. Vol. 32. No. 2. P. 199–205. DOI: 10.1037/neu0000383.
41. The role of brain derived neurotrophic factor in central nervous system / Y. Li, F. Li, D. Qin [et al.] // Front. Aging. Neurosci. 2022. No. 14. Article ID 986443. DOI: 10.3389/fnagi.2022.986443.
42. The roles of ciliary neurotrophic factor – from neuronutrition to energy metabolism / H. Guo, P. Chen, R. Luo [et al.] // Protein Pept. Lett. 2022. Vol. 29. No. 10. P. 815–828. DOI: 10.2174/0929866529666220905105800.
43. Val66Met functional polymorphism and serum protein level of brain-derived neurotrophic factor (BDNF) in acute episode of schizophrenia and depression / M. Skibinska, A. Groszewska, P. Kapelski [et al.] // Pharmacol. Rep. 2018. Vol. 70. No. 1. P. 55–59. DOI: 10.1016/j.pharep.2017.08.002.
Review
For citations:
Bodienkova G.M., Shchepina M.O. The role of the BDNF (rs6265) and CNTF (rs1800169) gene polymorphic variants in the development and progression of neurological disorders. Yakut Medical Journal. 2023;(3):102-106. https://doi.org/10.25789/YMJ.2023.83.25
Views:
18
Email this article 